Warm autoimmune hemolytic anemia (WAIHA) is a rare autoimmune disorder characterized by the destruction of red blood cells by antibodies produced by the body's immune system. These antibodies target red blood cells at body temperature (around 37°C), leading to their premature destruction and causing anemia. Common symptoms include fatigue, pallor, jaundice, and shortness of breath, and treatment typically involves corticosteroids, immunosuppressive therapy, and, in severe cases, splenectomy. WAIHA can occur at any age but is more commonly diagnosed in adults, particularly women.
Patients are the experts in their condition and advocacy groups provide a platform for patient voices. Working directly with these communities is the key to pushing research forward in an inclusive way.
Warm Autoimmune Hemolytic Anemia (WAIHA) is a relatively rare autoimmune disorder characterized by the destruction of red blood cells by the body's own immune system. By advocating for research, support initiatives, and access to resources, Leapcure strives to make a meaningful difference in the lives of individuals living with WAIHA.
Read more...
We’ve committed to having 500,000 conversations in the next three years, to equip ourselves and our Pharma partners with the insights needed to increase predictability.
Read more...
The ever-growing investment in advocacy doesn’t appear to be slowing down, and research is certainly seeing the benefits. Which at the end of the day, means better patient care and more options for patients.
Read more...
We’re ready to keep forming links between our Advocacy friends and Pharma partners, so these fruitful relationships continue to evolve beyond the study-to-study view.
Read more...